Oxford BioDynamics
Biotechnology company, which is engaged in biomarker research and development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 29.9x EV/Revenue -2.0x EV/EBITDA | round | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | 000k | ||
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (25 %) | (55 %) | 231 % | 25 % | 127 % | 60 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (957 %) | (1875 %) | (4710 %) | (1707 %) | (1473 %) | (649 %) | (331 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (946 %) | (1960 %) | (4357 %) | (2123 %) | (1819 %) | (762 %) | (403 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 263 % | 342 % | 149 % | 127 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Oxford BioDynamics Plc is a biotechnology company specializing in the development of epigenetic biomarkers using its proprietary EpiSwitch™ platform. The company operates in the personalized medicine market, focusing on early detection and stratification of diseases such as neurodegenerative disorders and cancer. Its clients include pharmaceutical companies, healthcare providers, and research institutions in the US, Europe, and Asia. The business model revolves around providing biomarker discovery services and licensing its technology to partners. Revenue is generated through service fees, licensing agreements, and collaborative research projects.
Keywords: epigenetics, biomarkers, personalized medicine, EpiSwitch™, neurodegenerative diseases, cancer, pharmaceutical, healthcare, biotechnology, diagnostics.
